A Phase 3 clinical trial investigating pulsed-field ablation (PFA) for Atrial Fibrillation reached its primary completion milestone on 2025-09-01. The study, which randomized 60 participants, compares PFA to a sham ablation control.
Background
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting millions worldwide. It is characterized by irregular and often rapid heart rates, which can lead to symptoms such as palpitations, fatigue, and shortness of breath. AF significantly increases the risk of stroke, heart failure, and other cardiovascular complications. Current treatment strategies include medication to control heart rate and rhythm, anticoagulation to prevent blood clots, and catheter ablation procedures. Catheter ablation aims to isolate or destroy areas of heart tissue that trigger or sustain AF. While effective, traditional ablation methods carry risks, and there is ongoing research into novel energy sources, such as pulsed-field ablation, to improve safety and efficacy.
Trial design
This study, titled "Pulsed-field Ablation Vs. Sham Ablation to Treat AF", is a Phase 3, single-blind, multicenter, prospective, randomized clinical trial. It enrolled 60 participants diagnosed with Atrial Fibrillation. Participants were randomized 1:1 to one of two arms: (i) an EP study followed by Pulsed-field Ablation (PFA), or (ii) an EP study followed by a Sham ablation control. After obtaining informed consent, an implantable loop recorder (ILR) was implanted within seven days, and an EP study was scheduled approximately 30 days after ILR implantation. Patients in both groups underwent an EP study to rule out a concealed AV bypass tract and supraventricular tachycardia (SVT) before randomization.
What this means
The primary completion of this Phase 3 trial signifies a crucial step forward in the evaluation of pulsed-field ablation as a potential treatment for atrial fibrillation. While no results have been reported yet, reaching this milestone indicates that data collection for the study's primary endpoint has concluded. The comparison of PFA against a sham ablation control in a randomized setting is designed to provide robust evidence regarding the efficacy and safety of PFA. The eventual analysis and publication of these results will be important for clinicians and patients, potentially informing future guidelines and treatment options for managing atrial fibrillation.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT05717725, titled "Pulsed-field Ablation Vs. Sham Ablation to Treat AF", was updated to reflect primary completion on 2025-09-01 on clinicaltrials.gov.